GTC Biotherapeutics (GTCB) Posts Q4 Loss of $0.09, Narrower Y/Y
GTC Biotherapeutics, Inc. (NASDAQ: GTCB) reports Q4 loss of $0.09, versus $0.62 reported for the same period a year ago. Revenue for the quarter was $1.2 million, compared to $1.0 million in Q408.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
- Semtech Corp (SMTC) Misses Q1 EPS by 4c; Guides Q2
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
